Understanding and Treating Glioblastoma

Wolfgang Wick,Michael Platten

DOI: https://doi.org/10.1016/j.ncl.2018.04.006

IF: 3.787

2018-08-01

Neurologic Clinics

Abstract:For newly diagnosed patients, the standard has remained largely unchanged for the past decade and concept-driven approaches like anti-angiogenic therapies or use of molecularly targeted drugs in all-comers populations have failed. Tumor-treating fields appear as a new option. Most current immunotherapy or molecularly targeted, precision medicine trials are also focusing on this newly diagnosed patient population. At progression, no standard exists and most treatments offer little beyond supportive care. Past trials lacked target precision and all-comers approaches have produced false negative results. Molecular precision approaches at progression need workup of recent rather than archival tissue.

neurosciences,clinical neurology